Director of Nonclinical Safety, Cambridge, MA

About this role

Isomorphic Labs is applying frontier AI to help unlock deeper scientific insights, faster breakthroughs, and life-changing medicines with an ambition to solve all disease.

The future is coming. A future enabled and enriched by the incredible power of machine learning. A future in which diseases are curtailed or cured starting with better and faster drug discovery.

Come and be part of an interdisciplinary team driving groundbreaking innovation and play a meaningful role in contributing towards us achieving our ambitious goals, while being a part of an inspiring and collaborative culture.

The world we want tomorrow is the one we’re building today. It starts with the culture at this company. It starts with you.

About Iso

Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.

Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI’s powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drugs will perform and develop innovative medicines to treat and cure some of the world’s most devastating diseases.

We have built a world-leading drug design engine comprising AI models that are capable of working across multiple therapeutic areas and drug modalities. We are continually innovating on model architecture and developing cutting-edge capabilities to advance rational drug design.

Every day, and with each new breakthrough, we’re getting closer to the promise of digital biology, and achieving our ambitious mission to one day solve all disease with the help of AI.

Isomorphic Labs was launched in 2021 to advance human health by building on and beyond the Nobel prize-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.

Our name comes from the belief that there is an underlying symmetry between biology and information science. By harnessing AI’s powerful capabilities, we can use it to model complex biological phenomena to help design novel molecules, anticipate how drug candidates will perform in the clinic and develop medicines to treat and cure some of the world’s most devastating diseases.

At IsoLabs, we are committed to leveraging state-of-the-art AI to advance precision medicine paradigms and establish new benchmarks for both efficacy and safety by consistently delivering the optimal treatments to the appropriate patients at precisely the right time, which we expect to significantly enhance our overall probability of success.

Since our founding, we have grown a world-class interdisciplinary team led by founder and CEO Sir Demis Hassabis and President Max Jaderberg. We have built strategic drug discovery collaborations with partners including Eli Lilly, Novartis and Johnson & Johnson, with the Novartis collaboration expanding in February 2025 to double its original scope. Our internal drug candidate pipeline consists of multiple programs across oncology and immunology.

In March 2025, IsoLabs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and Alphabet. In May 2026, IsoLabs raised $2.1 billion in a Series B financing round. This investment will power our world-leading AI drug design engine, scale our business globally and progress our drug candidate pipeline. The round was led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding our global capital base.Isomorphic Labs is scaling globally, with headquarters in London and offices in Lausanne, Switzerland and a US base in Cambridge, Massachusetts. We continue to progress our internal candidate programs towards the clinic while advancing across a broad range of modalities including small molecules, molecular glues, peptides, and antibodies.

Your impact

We are seeking a highly motivated and experienced Director of Nonclinical Safety to build our nonclinical safety function supporting programs in the Early Development phase.

Reporting directly to the Head of Early Development, you will serve as a key member of the Early Development team. In this critical role, you will be primarily responsible for defining and executing phase-appropriate nonclinical safety strategies as well as pioneering the integration of artificial intelligence in support of oncology and non-oncology programs.

What you will do

Functional Leadership & Capability Building

• Lead, build, and scale the Nonclinical Safety function within an AI-first drug development environment.

• Serve as the primary internal expert for post-IND nonclinical safety ensuring quality, consistency, and scalability as compounds transition into clinical trials.

• Establish a critical data feedback loop: ensure high-quality data are fed back to computational teams to continuously train, validate, and refine our predictive nonclinical safety AI models.

Portfolio & Program Strategy

• Define and drive nonclinical safety and other translational strategies primarily for small molecule drug candidates in the Early Development phase across oncology and non-oncology indications.

• Execute seamlessly on post-IND (NDA/MAA-enabling) nonclinical toxicology work, including chronic, reproductive, and carcinogenicity studies as needed.

• Establish translational strategies by integrating exploratory nonclinical safety biomarkers and exposure-based modeling plans to predict and de-risk potential effects in humans.

•

Similar jobs

• Director of Clinical Pharmacology, Cambridge, MA — Isomorphiclabs · Cambridge, MA
• Director, Nonclinical Development — Organon · Florham Park, New Jersey, United States | Plymouth Meeting, Pennsylvania, United States
• Director, Nonclinical Safety, Pathology — Gilead Sciences · Foster City, California, United States
• Senior Director Nonclinical Development — Viatris · Remote
• Medical Director, Clinical Development (Oncology), Cambridge, MA — Isomorphiclabs · Cambridge, MA
• Senior Director, Global Clinical Safety — Edwards Lifesciences · California – Irvine, United States
• Director, Study Quality and Compliance - Nonclinical Safety/Toxicology — Novartis · Cambridge (USA)
• Senior Director, Clinical Pharmacology — Amylyx · Remote